MSD’s Phase IIb study of tulisokibart achieves primary endpoint
MSD has reported that the Phase IIb MK-7240-012 study of tulisokibart achieved its primary endpoint for patients with moderate to severe HS.
The post MSD’s Phase IIb study of tulisokibart achieves primary endpoint appeared first on Clinical Trials Arena .